ACG Guideline-Recommended Testing
tTG-IgA as first-line test per American College of Gastroenterology guidelines3
ACG Guideline-Recommended Testing
tTG-IgA as first-line test per American College of Gastroenterology guidelines3
Complete IgA & IgG Coverage
Dual-class antibody detection for IgA-deficient patients with IgG-based alternatives
Reference standard for EMA testing
IFA on primate esophagus, the classical high-specificity confirmatory assay used in guideline-aligned celiac disease workflows 3
Deamidated Gliadin Peptide (DGP) Assays
Enhanced sensitivity with GAF-3X gliadin for comprehensive celiac screening 2,4
Celiac disease (CD) is a chronic autoimmune disorder in which the ingestion of gluten triggers an immune response that damages the small intestine which impairs nutrient absorption and leads to a range of gastrointestinal and systemic symptoms.1 Euroimmun offers solutions enabling the detection of antibodies against tissue transglutaminase (tTG) and deamidated gliadin peptide (DGP), which are key serological markers for CD.2,3
Diagnosis of CD relies on a combination of clinical assessment, biopsy, and serological detection of disease-specific autoantibodies.3 The American College of Gastroenterology recommends detection of tTG-IgA antibodies as the first-line test for suspected CD.3 Individuals should also be tested for total serum IgA, as IgA deficiency requires alternative testing using IgG-based assays such as DGP-IgG or tTG-IgG.3 While an intestinal biopsy is required to confirm the diagnosis in most cases, a non-biopsy strategy may be considered in select pediatrics when tTG-IgA levels exceed 10 times the upper limit of normal and a positive endomysial antibody IgA (EMA) test is confirmed on a second blood sample.3
Euroimmun offers a portfolio of serological assays to aid with celiac disease testing, including ELISAs for the detection of ttG and DGP antibodies of both IgA and IgG classes, as well as an immunofluorescence assay for the detection of EMA (IgA).
References
For in vitro diagnostic use.
2026 Euroimmun US
Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap